REMS Use Declining, But Post-Marketing Requirements Remain

Not surprisingly, FDA is imposing REMS less frequently in the fourth year of its new post-marketing authorities. But mandatory trial requirements appear to be rising, as is the use of the most burdensome type of REMS.

Michael McCaughan

So far in 2011, FDA has released at least 85 products from their requirements for Risk Evaluation & Mitigation Strategies,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet